Real estate
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
With pharma and biotech companies fighting for elbow room in the Bay Area where space comes at a premium, it should come as no surprise that some companies are spending big bucks on the space they desire in one of the most vibrant pharma hubs in the world.
The manufacturing plant will produce lentiviral vector for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.
Flagship Pioneering closed out a monster pool of funds to support a number of pioneering life science companies. Cambridge, Mass.-based Flagship secured $824 million in a new capital pool to boost companies that launch from its Flagship Labs incubator unit.
Medical device company receives second FDA clearance, adding blood flow monitoring technology to portfolio
New medical center to offer an array of specialties and super specialties with in-house support for physiotherapy, radiology & ultrasound services
While real estate developers are building new spaces for life science companies in the Bay Area, startups are struggling to find space.
During his two years in office, former Texas Secretary of State Rolando Pablos flexed the muscles of his office to make recruiting biotech and pharma companies a priority.
The Vycellix team, which will initially include its senior executive and administrative staff, is scheduled to occupy the new space adjacent to the Moffitt Cancer Center in April.
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
PRESS RELEASES